US-based cloud-native software company SOPHiA GENETICS has announced that Mumbai-based startup Karkinos Healthcare, will partner with SOPHiA GENETICS and adopt the SOPHiA DDM Platform to advance cancer testing and research for blood cancers and solid tumours to underserved areas in low and middle-income countries.

The SOPHiA DDM Platform is designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect rare and challenging cases.

Karkinos Healthcare will use SOPHiA GENETICS' technology to expand its offerings, advance research and streamline workflow for a variety of blood cancers, including Myeloid cancer and Lymphoma. In addition, the company will analyse solid tumours for a variety of cancer types including ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers.

The SOPHiA DDM Platform offers tailored NGS-based workflows to streamline processes – from sample to report – to accelerate analysis. By using the SOPHiA DDM Platform, researchers from Karkinos Healthcare will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advance the use of precision medicine.